Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
- Cleveland Clinic Journal of Medicine
- August 2010,
- 77
- (8)
- 503-505;
- DOI: https://doi.org/10.3949/ccjm.77a.09167
In this issue
- Increased risk of severe acute pancreatitis in patients with diabetes
- Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study
- A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position
- Longer term safety of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta‐analysis
- Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function
- Incretin-Based Therapies
- Modulation of the Glucagon-Like Peptide-1 Receptor Signaling by Naturally Occurring and Synthetic Flavonoids
- Effect of metformin and pioglitazone on β-catenin and biochemical markers in sitagliptin-induced pancreatitis in diabetic rats
- In Reply: Type 2 diabetes prevention after acute pancreatitis
- Letter: Type 2 diabetes prevention after acute pancreatitis
- Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus
- Incretin-based therapies for type 2 diabetes mellitus: New therapeutic mechanisms
- Antihyperglycemic drugs and cardiovascular outcomes in type 2 diabetes